Integrated Analysis Identifies a Nine-microRNA Signature Biomarker for Diagnosis and Prognosis in Colorectal Cancer

Di, Ziyang; Di, Maojun; Fu, Weihua; Tang, Qiang; Liu, Yanwei; Lei, Peijie; Gu, Xinsheng; Liu, Tong; Sun, Min

doi:10.3389/fgene.2020.00192

Cited by 36 publications

(29 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-210, a hypoxia-regulated miRNA exhibits oncogenic properties in most cancers, where it mediates cell proliferation, migration, invasion, and clonogenicity [ 28 ]. It has been identified along with eight other miRNA as potentially useful diagnostic biomarkers in CRC tissues [ 29 ]. Many reported its potential diagnostic value as it is upregulated in the serum of CRC patients similarly to our data in plasma [ 16 , 26 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. Stage IV CRC patients have poor prognosis with a five-year survival rate of 14%. Liver metastasis is the main cause of mortality in CRC patients. Since current screening tests have several drawbacks, effective stable non-invasive biomarkers such as microRNA (miRNA) are needed. We aim to investigate the expression of miRNA (miR-21, miR-19a, miR-23a, miR-29a, miR-145, miR-203, miR-155, miR-210, miR-31, and miR-345) in the plasma of 62 Lebanese Stage IV CRC patients and 44 healthy subjects using RT-qPCR, as well as to evaluate their potential for diagnosis of advanced CRC and its liver metastasis using the Receiver Operating Characteristics (ROC) curve. miR-21, miR-145, miR-203, miR-155, miR-210, miR-31, and miR-345 were significantly upregulated in the plasma of surgery naïve CRC patients when compared to healthy individuals. We identified two panels of miRNA that could be used for diagnosis of Stage IV CRC (miR-21 and miR-210) with an area under the curve (AUC) of 0.731 and diagnostic accuracy of 69% and liver metastasis (miR-210 and miR-203) with an AUC = 0.833 and diagnostic accuracy of 72%. Panels of specific circulating miRNA, which require further validation, could be potential non-invasive diagnostic biomarkers for CRC and liver metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The absence of highly effective and specific biomarkers for predicting the prognosis remains a challenge in clinical management of CRC patients. The recent rapid development of omics technologies such as genomes, transcriptomes, and proteomes provides new hope for establishing valuable prognostic models for CGC 6 – 10 . However, the detection of large-scale expression levels of mRNAs, micro RNAs, long noncoding RNAs, or DNA polymorphisms could lead to variations due to different platforms and techniques used in the studies 11 , 12 .…”

Section: Discussionmentioning

confidence: 99%

The Development of Three-DNA Methylation Signature as a Novel Prognostic Biomarker in Patients with Colorectal Cancer

Gong

Ye²,

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Aims. The prognosis of colorectal cancer (CRC) remains poor. This study aimed to develop and validate DNA methylation-based signature model to predict overall survival of CRC patients. Methods. The methylation array data of CRC patients were retrieved from The Cancer Genome Atlas (TCGA) database. These patients were divided into training and validation datasets. A risk score model was established based on Kaplan-Meier and multivariate Cox regression analysis of training cohort and tested in validation cohort. Results. Among total 14,626 DNA methylation candidate markers, we found that a three-DNA methylation signature (NR1H2, SCRIB, and UACA) was significantly associated with overall survival of CRC patients. Subgroup analysis indicated that this signature could predict overall survival of CRC patients regardless of age and gender. Conclusions. We established a prognostic model consisted of 3-DNA methylation sites, which could be used as potential biomarker to evaluate the prognosis of CRC patients.

show abstract

“…The area under the ROC curve for 1-year, 3-year and 5-year OS were 0.771, 0.734 and 0.687, which implied that our signature had excellent predictive power (Fig. 2C-E) [18,19]. We conducted a hierarchical analysis to clarify the link between subgroups and risk grouping.…”

Section: Construction Of Signaturementioning

confidence: 92%

Stem Cell-Related Prognostic Signature for Lung Adenocarcinoma

Huang

Shi

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Adenocarcinoma is characterized by high infiltration and negative growth, which is easy to invade the walls of blood vessels and lymphatic vessels. The function of the stem cell population is to control and maintain cell regeneration. Therefore, it is necessary to study the prognostic value of stem cells in LUAD.Methods: Stem cells signature construction relies on the univariate, least absolute shrinkage operator (LASSO) and multivariate Cox regression analysis. Risk plot, Kaplan-Meier analysis and the area under ROC (AUC) are verified the accuracy of the signature in GEO (GSE20319 and GSE42127) and TCGA cohort respectively. What's more, to further improve persuasiveness, we conducted nomogram, drug efficacy analysis, immune infiltration analysis, and compared the relationship between mRNA stem cell index (mRNAsi) and signature.Result: The patients were divided into two groups via the cutoff of risk score; it can be seen that the low-risk group has better survival. The robust signature that contains ten stem cells is independent prognostic factors for LUAD (C6orf62, DNER, NELL2, LATS2, LGR5, PTPRO, LRIG1, PABPC1, NT5E and SET). The nomogram showed that 1-year (0.805), 3-year (0.773), and 5-year (0.765) survival rates of the signature we constructed were all greater than 0.7, indicating that our signature was very feasible.Conclusion: The signature can be used as a reliable and convenient tool for lung adenocarcinoma.

show abstract

Integrated Analysis Identifies a Nine-microRNA Signature Biomarker for Diagnosis and Prognosis in Colorectal Cancer

Cited by 36 publications

References 52 publications

Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis

Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis

The Development of Three-DNA Methylation Signature as a Novel Prognostic Biomarker in Patients with Colorectal Cancer

Stem Cell-Related Prognostic Signature for Lung Adenocarcinoma

Contact Info

Product

Resources

About